Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma

RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Infusions of a person's white blood cells may be able to replace immune cells that were destroyed by chemotherapy. Combining fludarabine with vaccine therapy and white blood cell infusions may kill more tumor cells.

PURPOSE: This randomized phase I trial is studying the side effects of giving vaccine therapy together with fludarabine and white blood cell infusions and to see how well it works in treating patients with unresectable or metastatic melanoma.

Studie Overzicht

Gedetailleerde beschrijving

OBJECTIVES:

Primary

  • Determine the toxicity and immune effects of vaccination comprising modified gp100 peptide (gp100:209-217[210M]), Montanide ISA-51, and keyhole limpet hemocyanin followed by peripheral blood mononuclear cell reinfusion after treatment-induced lymphopenia with fludarabine in patients with unresectable or metastatic melanoma.
  • Determine the induction of antigen-specific T-cell responses in patients treated with this regimen.
  • Determine the kinetics and duration of immune response in patients treated with this regimen.
  • Compare the immunologic effects of this regimen in these patients with historical results.

Secondary

  • Compare 2 different dosing schedules of fludarabine, in terms of induction of lymphopenia and granulocytopenia and on the induction of a specific immune response to this vaccine, in these patients.

OUTLINE: This is a pilot, randomized study. Patients are randomized to 1 of 2 treatment arms.

Within 2 weeks before the start of fludarabine, all patients undergo leukapheresis over 4-6 hours for the collection of peripheral blood mononuclear cells (PBMCs).

  • Arm I: Patients receive fludarabine IV over 30 minutes on days 1-5.
  • Arm II: Patients receive fludarabine as in arm I on days 1, 3, and 5. In both arms, patients receive autologous PBMCs IV over approximately 30 minutes on day 8 and vaccination comprising gp100:209-217(210M) peptide, Montanide ISA-51, and keyhole limpet hemocyanin subcutaneously on days 8, 22, 36, 50, and 64. Patients with stable or responding disease continue to receive vaccination on day 78 and then every 28-31 days for up to 1 year.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 20 patients (10 per treatment arm) will be accrued for this study within 2 years.

Studietype

Ingrijpend

Inschrijving (Verwacht)

20

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Oregon
      • Portland, Oregon, Verenigde Staten, 97213-2967
        • Providence Cancer Center at Providence Portland Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed malignant melanoma

    • Metastatic or unresectable disease
  • Measurable disease
  • HLA-A2 positive
  • Received at least 1 prior immunotherapy and/or chemotherapy regimen for metastatic disease (first 6 patients only)
  • No known brain metastases unless previously treated with radiotherapy and/or surgery AND is stable for at least 1 month after treatment

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2 OR
  • Karnofsky 60-100%

Life expectancy

  • More than 3 months

Hematopoietic

  • WBC ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Absolute lymphocyte count ≥ 500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10 g/dL (transfusions allowed)
  • Hematocrit ≥ 24%
  • No other active bleeding

Hepatic

  • Bilirubin < 2 times upper limit of normal (ULN) (unless due to Gilbert's disease)
  • AST and ALT < 3 times ULN
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative

Renal

  • Creatinine < 2 mg/dL
  • No uncontrolled hypercalcemia

Cardiovascular

  • No uncontrolled symptomatic congestive heart failure
  • No unstable angina pectoris
  • No uncontrolled cardiac arrhythmia
  • No uncontrolled hypertension

Pulmonary

  • No uncontrolled bronchospasm
  • No hemoptysis

Immunologic

  • Negative serology for all of the following:

    • HIV-1 and HIV-2
    • HTLV-1 and -2
    • Syphilis
  • Rheumatoid factor < 43 units/μL
  • Anti-nuclear antibody < 11 units/μL
  • No history of multiple sclerosis, systemic lupus erythematosus, or myasthenia gravis
  • No primary or secondary immunodeficiency
  • No active infection
  • No allergy to seafood or shellfish that would preclude study participation

Other

  • No active gastrointestinal bleeding
  • No uncontrolled hyperglycemia
  • No other medical or psychiatric condition or social situation that would preclude study compliance
  • No other uncontrolled illness
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3-4 months after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • No prior immunization with gp100:209-217(210M) peptide

Chemotherapy

  • See Disease Characteristics
  • More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

  • More than 2 weeks since prior steroid therapy except replacement steroids or inhaled steroids
  • No concurrent corticosteroids except replacement steroids
  • No concurrent dexamethasone

Radiotherapy

  • See Disease Characteristics
  • More than 2 weeks since prior radiotherapy

Surgery

  • See Disease Characteristics
  • Recovered from prior surgery

Other

  • No other concurrent investigational agents
  • No other concurrent anticancer therapy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Toxicity by clinical and laboratory observation at 1 month
Antigen-specific T-cell responses by tetramer analysis, ELISPOT, and cytokine flow cytometry periodically

Secundaire uitkomstmaten

Uitkomstmaat
Compare 2 different dosing schedules of fludarabine in terms of lymphocyte recovery using a complete blood count periodically
Tumor regression by standard imaging at study completion

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Walter J. Urba, MD, PhD, Providence Cancer Center, Earle A. Chiles Research Institute

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 juli 2004

Primaire voltooiing (Werkelijk)

1 maart 2010

Studie voltooiing (Werkelijk)

1 maart 2010

Studieregistratiedata

Eerst ingediend

7 september 2004

Eerst ingediend dat voldeed aan de QC-criteria

7 september 2004

Eerst geplaatst (Schatting)

8 september 2004

Updates van studierecords

Laatste update geplaatst (Schatting)

4 april 2013

Laatste update ingediend die voldeed aan QC-criteria

2 april 2013

Laatst geverifieerd

1 augustus 2009

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren